The effect of pomegranate extract on coronary artery atherosclerosis in SR-BI/APOE double knockout mice

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 80-89

  Al Jarallah, Aishah ^a,b,c   Igdoura, Fatima ^b   Zhang, Yi ^b   Tenedero, Christine B ^b   White, Elizabeth J ^a   MacDonald, Melissa E ^b   Igdoura, Suleiman A ^a   Trigatti, Bernardo L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Atherosclerosis; Coronary arteries; Inflammation; Oxidative stress; Pomegranate extract

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; POMEGRANATE EXTRACT; SCAVENGER RECEPTOR BI; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AORTA SINUS; ARTICLE; ATHEROSCLEROTIC PLAQUE; ATTENUATION; CARDIOMEGALY; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE; HEART MUSCLE FIBROSIS; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; POMEGRANATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL ESTERS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; FEMALE; LIPOPROTEINS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MYOCARDIUM; OXIDATIVE STRESS; PLANT EXTRACTS; PLAQUE, ATHEROSCLEROTIC; PUNICACEAE; SCAVENGER RECEPTORS, CLASS B; VASCULITIS;

EID: 84876800648     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.025     Document Type: Article

References (42)

1. Mallika V., Goswami B., Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 2007, 58(5):513-522.
2. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84(4):1381-1478.
3. De Rosa S., Cirillo P., Paglia A., Sasso L., Di Palma V., Chiariello M. Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach?. Curr Vasc Pharmacol 2010, 8(2):259-275.
4. Mente A., de Koning L., Shannon H.S., Anand S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009, 169(7):659-669.
5. Street D.A., Comstock G.W., Salkeld R.M., Schuep W., Klag M.J. Serum antioxidants and myocardial infarction. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction?. Circulation 1994, 90(3):1154-1161.
6. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334(18):1145-1149.
7. Omenn G.S., Goodman G.E., Thornquist M.D., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334(18):1150-1155.
8. Rapola J.M., Virtamo J., Ripatti S., et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997, 349(9067):1715-1720.
9. Shihabi A., Li W.G., Miller F.J., Weintraub N.L. Antioxidant therapy for atherosclerotic vascular disease: the promise and the pitfalls. Am J Physiol Heart Circ Physiol 2002, 282(3):H797-H802.
10. Cook N.R., Albert C.M., Gaziano J.M., et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007, 167(15):1610-1618.
11. Witte K.K., Clark A.L. Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Fail Rev 2006, 11(1):65-74.
12. Seeram N.P., Adams L.S., Henning S.M., et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005, 16(6):360-367.
13. Basu A., Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev 2009, 67(1):49-56.
14. Landete J.M. Updated knowledge about polyphenols: functions, bioavailability, metabolism, and health. Crit Rev Food Sci Nutr 2012, 52(10):936-948.
15. Hassanpour Fard M., Ghule A.E., Bodhankar S.L., Dikshit M. Cardioprotective effect of whole fruit extract of pomegranate on doxorubicin-induced toxicity in rat. Pharm Biol 2011, 49(4):377-382.
16. Aviram M., Rosenblat M., Gaitini D., et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004, 23(3):423-433.
17. Aviram M., Dornfeld L., Kaplan M., et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp Clin Res 2002, 28(2-3):49-62.
18. Aviram M., Dornfeld L., Rosenblat M., et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000, 71(5):1062-1076.
19. Aviram M., Volkova N., Coleman R., et al. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem 2008, 56(3):1148-1157.
20. Kaplan M., Hayek T., Raz A., et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001, 131(8):2082-2089.
21. Rosenblat M., Volkova N., Aviram M. Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2. Atherosclerosis 2010, 212(1):86-92.
22. Braun A., Rigotti A., Trigatti B.L. Myocardial infarction following atherosclerosis in murine models. Curr Drug Targets 2008, 9(3):217-223.
23. Braun A., Trigatti B.L., Post M.J., et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002, 90(3):270-276.
24. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999, 68:523-558.
25. Al-Jarallah A., Trigatti B.L. A role for the scavenger receptor, class B type I in high density lipoprotein dependent activation of cellular signaling pathways. Biochim Biophys Acta 2010, 1801(12):1239-1248.
26. Braun A., Yesilaltay A., Acton S., et al. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis 2008, 198(1):77-84.
27. Braun A., Zhang S., Miettinen H.E., et al. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci U S A 2003, 100(12):7283-7288.
28. Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207(1):16-23.
29. Zanetti M., d'Uscio L.V., Peterson T.E., Katusic Z.S., O'Brien T. Analysis of superoxide anion production in tissue. Methods Mol Med 2005, 108:65-72.
30. Covey S.D., Krieger M., Wang W., Penman M., Trigatti B.L. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2003, 23(9):1589-1594.
31. Rigotti A., Trigatti B.L., Penman M., Rayburn H., Herz J., Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997, 94(23):12610-12615.
32. Trigatti B., Rayburn H., Vinals M., et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A 1999, 96(16):9322-9327.
33. Biasillo G., Leo M., Della Bona R., Biasucci L.M. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 2010, 5(3):225-233.
34. Chu V., Otero J.M., Lopez O., Morgan J.P., Amende I., Hampton T.G. Method for non-invasively recording electrocardiograms in conscious mice. BMC Physiol 2001, 1:6.
35. de Nigris F., Williams-Ignarro S., Lerman L.O., et al. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc Natl Acad Sci U S A 2005, 102(13):4896-4901.
36. Ping D., Boekhoudt G.H., Rogers E.M., Boss J.M. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 1999, 162(2):727-734.
37. Dewald O., Zymek P., Winkelmann K., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005, 96(8):881-889.
38. Xia Y., Frangogiannis N.G. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets 2007, 6(2):101-107.
39. Zhang S., Picard M.H., Vasile E., et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 2005, 111(25):3457-3464.
40. Yancey P.G., de la Llera-Moya M., Swarnakar S., et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 2000, 275(47):36596-36604.
41. Lee J.Y., Badeau R.M., Mulya A., et al. Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. J Lipid Res 2007, 48(5):1052-1061.
42. Tzulker R., Glazer I., Bar-Ilan I., Holland D., Aviram M., Amir R. Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J Agric Food Chem 2007, 55(23):9559-9570.